Monalizumab
(Anti-human CD159a mAb, human IgG4-Kappa; IPH2201)
Catalog No.: PC-Ab1087Not For Human Use, Lab Use Only.
Monalizumab (IPH2201) is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. The first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. Monalizumab targets NKG2A receptors expressed on tumor infiltrating cytotoxic CD8 T lymphocytes and NK cells. NKG2A is an inhibitory receptor binding HLA-E. By expressin
Monalizumab (IPH2201) is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. The first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. Monalizumab targets NKG2A receptors expressed on tumor infiltrating cytotoxic CD8 T lymphocytes and NK cells. NKG2A is an inhibitory receptor binding HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells.
Physicochemical Properties
M.Wt
Formula
Human IgG4-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
